An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination

Boehringer Ingelheim

Status and phase: Completed; Phase 3

Conditions: Hypertension

Treatments: Drug: telmisartan40/amlodipine5; Drug: telmisartan80/amlodipine5

Study type: Interventional

Funder types: Industry

Identifiers

NCT00618774

1235.16

Details and patient eligibility

About

To assess the long term safety and efficacy of telmisartan plus amlodipine FDC in patients with essential hypertension who failed to control their BP with either monotherapy

Enrollment: 259 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients with essential hypertension
2. Outpatient

Exclusion criteria

• Patients whose SBP >=180 mmHg or DBP >=110 mmHg at the end of treatment visit of the double-blind treatment period in the "non-responder trials"
• Patients who have met any of the exclusion criteria defined in the "non-responder trials"